Tag archive for ‘Epi-Pen’
Antares Pharmaceuticals: Highlights of Presentation at JP Morgan Conference (ATRS, $2.36. Buy)
Investment Overview Antares has hit a somewhat dis-settling stretch as Otrexup prescriptions have recently flattened and the FDA recommended that additional patients be enrolled in the safety evaluation of the QST phase 3 trial. I see these as typical of issues that always arise with biopharma companies and can be reasonably resolved. I remain confident […]